Evidence map›Paper›PMID 40019687›Full record

ArticleInflammopharmacology2025

Gefitinib as an antimalarial: unveiling its therapeutic potential.

Varun Gorki, Neha Sylvia Walter, Monika Chauhan, Neelima Dhingra, Upma Bagai, Sukhbir Kaur

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Varun Gorki *Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India.
Neha Sylvia Walter *Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India.
Monika ChauhanUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
Neelima DhingraUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
Upma BagaiParasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India.
Sukhbir KaurParasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India. sukhbir@pu.ac.in.ORCID http://orcid.org/0000-0001-9071-7950

Funding

University Grants Commission UGC-CAS II
6 · The paper itself

Abstract

Resistant strains of Plasmodium spp. pose a great threat to healthcare. Drug repurposing is a smart, and an effective way to look for new alternatives for different ailments including malaria. Protein tyrosine kinases (PTKs) play a crucial role in growth, maturation as well as differentiation of Plasmodium and this study explores antimalarial activity of PTKs inhibitor gefitinib using in silico and experimental approaches. The drug showed considerable inhibitory activity against P. falciparum 3D7 (IC

Indexed as

AntimalarialsGefitinibMalariaAnimalsArtesunateDose-Response Relationship, DrugDrug RepositioningDrug SynergismHumansMicePlasmodium bergheiPlasmodium falciparumProtein Kinase InhibitorsAntimalarialsArtesunateGefitinibProtein Kinase InhibitorsAntimalarial activityGefitinibMalariaPlasmodiumTyrosine kinase inhibitors

Identifiers

PMID40019687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.